The Treatment of Peyronie’s Disease by Iontophoresis Of C
            <sub>21</sub>
            Esterified Glucocorticoids

Rothfeld, Samuel H.; Murray, William S.

doi:10.1016/s0022-5347(17)63139-2

Cited by 44 publications

(8 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As the cause of PD remains obscure it is not surprising that many treatment options have been tried for this condition (Table 1[19,24–46]). Treatment should be aimed at patients with early inflammatory disease and to prevent the destruction of the tunical architecture, in particular the relationship between the outer and inner tunical layers.…”

Section: Managementmentioning

confidence: 99%

The management of Peyronie's disease

Ralph

Minhas

2003

BJU International

View full text Add to dashboard Cite

Section: Managementmentioning

confidence: 99%

The management of Peyronie's disease

Ralph

Minhas

2003

BJU International

View full text Add to dashboard Cite

“…Absorption through the skin is an important alternative or adjunct to traditional methods of drug delivery. In patients with Peyronie's disease transdermal iontophoretic administration of steroids [5–7] or orgotein [8,9] has shown promising results without the side‐effects associated with oral or intraplaque injection therapies. Two clinical studies using different methods showed that transdermal electromotive administration (TEA) of verapamil and dexamethasone, with or without lidocaine, was beneficial in patients with Peyronie's disease [10,11].…”

Section: Introductionmentioning

confidence: 99%

Transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease

et al. 2003

View full text Add to dashboard Cite

OBJECTIVETo evaluate the effects of the transdermal electromotive administration of verapamil and dexamethasone on plaque size, penile deviation, pain, erectile function and capacity for vaginal penetration in patients with Peyronie's disease. PATIENTS AND METHODSForty-nine patients were treated four times weekly for six consecutive weeks. During each session the drug mixture was administered from a receptacle fixed to the skin overlying the plaques, using 2.4 mA pulsed current for 20 min. Plaque size and penile deviation were evaluated by dynamic penile duplex ultrasonography, X-ray and photographs; pain, erectile function and capacity for vaginal penetration were assessed using a questionnaire. Vital signs and side-effects were recorded. Differences before and after treatment were assessed. RESULTSThe plaque disappeared in 8% of patients, with a measurable reduction in volume in 74% and no change in 18% ( P < 0.001). Penile deviation resolved in 10% of the men, decreased in 74% and remained unchanged in 16% ( P < 0.001). The plaque volume was halved in two-thirds of the men, to a mean ( SD ) of 515 (301) mm 3 , and the penile deviation halved in 45% of patients, to 24 (5) ∞ ; pain was completely eliminated in 88% ( P < 0.001). Erectile function was completely restored in 42% of patients with initial erectile dysfunction and improved in 17% ( P < 0.001); vaginal penetration improved in 73%. No toxicity was noted, except for a transient skin erythema at the site of the penile and dispersive electrodes.

show abstract

“…12 The use of dexamethasone rests on occasional case reports 13,14 and the effectiveness of the verapamil-dexamethasone combination in 3 uncontrolled studies. 6 -8 Its mode of electromotive administration is unusual.…”

Section: Discussionmentioning

confidence: 99%

740 Prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease

Stasi¹,

Giannantoni²,

Stephen³

et al. 2004

European Urology Supplements

View full text Add to dashboard Cite

Purpose: Uncontrolled studies with intraplaque electromotive administration of verapamil and dexamethasone have demonstrated objective improvements in Peyronie's disease. We performed a prospective controlled study to assess the efficacy of intraplaque electromotive verapamil/ dexamethasone vs electromotive lidocaine.Materials and Methods: Patients with Peyronie's disease were randomized into a study group (47 patients) and a control group (49 patients). For each treatment session an electrode receptacle was sited over the plaque and filled with either 5 mg verapamil and 8 mg dexamethasone (study group) or 2% lidocaine (control group), and a 2.4 mA electric current was applied for 20 minutes. All patients were scheduled for 4 sessions per week for 6 weeks. Assessment before and after treatment included measurements of plaque volume and penile curvature, and pain on erection (from questionnaire).Results: A total of 37 patients in the study group and 36 in the control group completed treatment courses. In the study group there were significant decreases in median plaque volume from 824 to 348 mm 3 , and in penile curvature from 43 to 21 degrees. In the control group median volume and curvature were unchanged. The difference in results after treatment between the 2 groups was also significant. Significant pain relief occurred in both groups, transient in the control group and permanent in the study group. All patients experienced temporary erythema at the electrode site. There were no other side effects.Conclusions: Intraplaque electromotive verapamil and dexamethasone induce substantial objective improvement in Peyronie's disease compared to electromotive lidocaine administration.

show abstract

The Treatment of Peyronie’s Disease by Iontophoresis Of C ₂₁ Esterified Glucocorticoids

Cited by 44 publications

References 2 publications

The management of Peyronie's disease

The management of Peyronie's disease

Transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease

740 Prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease

Contact Info

Product

Resources

About

The Treatment of Peyronie’s Disease by Iontophoresis Of C 21 Esterified Glucocorticoids

Cited by 44 publications

References 2 publications

The management of Peyronie's disease

The management of Peyronie's disease

Transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease

740 Prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease

Contact Info

Product

Resources

About

The Treatment of Peyronie’s Disease by Iontophoresis Of C ₂₁ Esterified Glucocorticoids